Brain Injection Promises to Erase Alzheimer’s Forever

Illustration of a human figure with a highlighted brain

Imagine a single injection turning your brain’s own cells into relentless hunters that erase Alzheimer’s plaques—potentially forever.

Story Snapshot

Washington University researchers engineered astrocytes to prevent plaques entirely in young mice and cut them by 50% in older ones.
One viral injection delivers CAR gene therapy, repurposing star-shaped brain cells into targeted cleaners.
This marks the first success in astrocyte engineering for amyloid beta removal, borrowed from cancer immunotherapy.
Offers hope for one-time treatments over frequent, costly antibody infusions like Leqembi.

Breakthrough Mechanism in Mouse Models

Marco Colonna’s team at Washington University School of Medicine injected a virus carrying a chimeric antigen receptor (CAR) gene into astrocytes of Alzheimer’s-model mice. These star-shaped cells normally support brain homeostasis. The CAR reprograms them to recognize and engulf amyloid beta plaques. Young mice received treatment before plaques formed; by six months, their brains stayed clear. Older mice with existing plaques saw 50% reduction after three months.

Astrocytes selectively targeted amyloid beta without harming healthy tissue. This precision stems from CAR technology, proven in cancer treatments where T-cells attack tumors. Here, researchers adapted it for brain glia cells, achieving durable effects from one dose. Mouse models mimic human Alzheimer’s plaque buildup, providing a strong preclinical foundation.

Distinctions from Existing Therapies

Antibody drugs like Leqembi and Kisunla clear plaques but demand repeated infusions, costing $26,000 yearly with side effects like brain swelling. Colonna’s approach uses the brain’s endogenous cells, avoiding external agents. Nanotherapies from IBEC restore blood-brain barriers for 50-60% rapid clearance, while Karolinska’s receptor agonists boost natural enzymes. None previously engineered astrocytes this way.

Microglia enhancements at Northwestern highlight variable efficacy due to genes like TREM2. Natural compounds from UCI aid clearance but lack specificity. CAR-astrocytes stand out for one-shot reprogramming; efficient, less invasive innovation over endless pharma dependency.

Lead Researchers and Institutional Drive

Marco Colonna, Robert Rock Belliveau Professor of Pathology, led the study. His motivation targets durable therapies for 50 million global Alzheimer’s sufferers. WashU provides neurodegeneration and immunotherapy expertise. Funding from NIH and groups like BrightFocus pushes translational research. Colonna calls this the first astrocyte engineering success for plaques.

Scientists turn brain cells into Alzheimer’s plaque cleaners

Scientists have developed a promising new approach to treating Alzheimer’s disease by turning ordinary brain cells into powerful plaque-clearing machines. Instead of requiring frequent antibody infusions like current…

— The Something Guy 🇿🇦 (@thesomethingguy) March 12, 2026

Decision-makers include Colonna as principal investigator, peer reviewers, and future FDA regulators. Pharma like Eisai and Biogen face competition, as this could disrupt multi-dose markets.

Timeline and Ongoing Progress

The study published March 11, 2026, following February’s Karolinska receptor findings and early March IBEC nanotherapy. Injections occurred at young or older stages; assessments confirmed outcomes after three months. Behavioral and memory tests in treated mice remain pending full details. No human trials announced; safety tests precede IND filing.

Short-term, this validates astrocyte targeting, accelerating brain cell therapies. Long-term, it promises paradigm shifts if translatable, slowing progression pre-symptoms. Patients, families, and caregivers stand to benefit most, with economic savings from lower dosing.